Westenbrink, Bd

List of Publications by Year
in descending order

81 papers	3,496 citations	218677 26 h-index	144013 57 g-index
85 all docs	85 docs citations	85 times ranked	4201 citing authors

#	Article	IF	Citations
1	The clinical and prognostic value of late Gadolinium enhancement imaging in heart failure with mid-range and preserved ejection fraction. Heart and Vessels, 2022, 37, 273-281.	1.2	8
2	Early detection of obstructive coronary artery disease in the asymptomatic high-risk population: objectives and study design of the EARLY-SYNERGY trial. American Heart Journal, 2022, 246, 166-177.	2.7	4
3	SGLT2 Inhibitors and Ketone Metabolism in Heart Failure. Journal of Lipid and Atherosclerosis, 2022, 11, 1.	3.5	25
4	Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?. European Journal of Heart Failure, 2022, 24, 287-298.	7.1	16
5	Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009238.	3.9	40
6	Reply to â€˜Exercise intolerance in heart failure: beyond mitochondrial dysfunctionâ€™. Letter regarding the article â€˜Exercise: a molecular tool to boost muscle growth and mitochondrial performance in heart failure?â€™. European Journal of Heart Failure, 2022, 24, 910-911.	7.1	0
7	The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction. Cardiovascular Research, 2021, 117, 2108-2124.	3.8	108
8	Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. Circulation: Heart Failure, 2021, 14, e007684.	3.9	87
9	Testosterone activates glucose metabolism through AMPK and androgen signaling in cardiomyocyte hypertrophy. Biological Research, 2021, 54, 3.	3.4	17
10	What You Did Not Know About Cardiac Ca 2+ Handling. Circulation, 2021, 143, 466-469.	1.6	2
11	ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca2+ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKIIΐ. International Journal of Molecular Sciences, 2021, 22, 4427.	4.1	9
12	Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2021, 77, 1660-1669.	2.8	111
13	Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction. ESC Heart Failure, 2021, 8, 2458-2466.	3.1	13
14	Importance of epicardial adipose tissue localization using cardiac magnetic resonance imaging in patients with heart failure with midâ€range and preserved ejection fraction. Clinical Cardiology, 2021, 44, 987-993.	1.8	22
15	Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction. Netherlands Heart Journal, 2021, 29, 383-393.	0.8	5
16	The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise. Pflugers Archiv European Journal of Physiology, 2021, 473, 1301-1313.	2.8	10
17	Gain-of-function mutation in ubiquitin ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues. Journal of Clinical Investigation, 2021, 131, .	8.2	22
18	Association of Circulating Ketone BodiesÂWith Functional Outcomes AfterÂST-Segment Elevation MyocardialÂInfarction. Journal of the American College of Cardiology, 2021, 78, 1421-1432.	2.8	21

#	Article	IF	Citations
19	Ketone bodies for the failing heart: fuels that can fix the engine?. Trends in Endocrinology and Metabolism, 2021, 32, 814-826.	7.1	26
20	Selenoprotein DIO2 Is a Regulator of Mitochondrial Function, Morphology and UPRmt in Human Cardiomyocytes. International Journal of Molecular Sciences, 2021, 22, 11906.	4.1	13
21	Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?. Cardiovascular Diabetology, 2020, 19, 5.	6.8	29
22	Mitochondrial therapy for doxorubicin cardiomyopathy: nuclear factor-ÎºB to the rescue?. Cardiovascular Research, 2020, 116, 1092-1094.	3.8	3
23	Myocardial adiposity in heart failure with preserved ejection fraction: the plot thickens. European Journal of Heart Failure, 2020, 22, 455-457.	7.1	4
24	Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the <scp>VIPâ€HF</scp> study. European Journal of Heart Failure, 2020, 22, 1923-1929.	7.1	25
25	Unraveling the Genotypeâ€Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesityâ€Related Cardiac Defects as a Major Disease Modifier. Journal of the American Heart Association, 2020, 9, e018641.	3.7	16
26	Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction. Cardiovascular Drugs and Therapy, 2020, 35, 953-963.	2.6	4
27	Effects of Sodiumâ€“Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. Cardiovascular Drugs and Therapy, 2020, 34, 311-321.	2.6	10
28	Temporal patterns of macrophageâ€•and neutrophilâ€•related markers are associated with clinical outcome in heart failure patients. ESC Heart Failure, 2020, 7, 1190-1200.	3.1	17
29	Aortic regurgitation, a forgotten valve disease in hypertrophic cardiomyopathy?. European Journal of Radiology, 2020, 126, 108971.	2.6	0
30	Sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin improves cardiac function in nonâ€diabetic rats with left ventricular dysfunction after myocardial infarction. European Journal of Heart Failure, 2019, 21, 862-873.	7.1	236
31	Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation, 2018, 138, 678-691.	1.6	229
32	Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure). Circulation: Heart Failure, 2018, 11, e004431.	3.9	13
33	Epicardial fat in heart failure patients with midâ€range and preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 1559-1566.	7.1	173
34	Identifying Pathophysiological Mechanisms in Heart Failure WithÂReduced Versus Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2018, 72, 1081-1090.	2.8	199
35	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American Heart Journal, 2017, 185, 140-149.	2.7	54
36	CaMKIIÎ´ subtypes differentially regulate infarct formation following ex vivo myocardial ischemia/reperfusion through NF-ÎºB and TNF-Î±. Journal of Molecular and Cellular Cardiology, 2017, 103, 48-55.	1.9	62

#	Article	IF	Citations
37	Selecting heart failure patients for metabolic interventions. Expert Review of Molecular Diagnostics, 2017, 17, 141-152.	3.1	5
38	Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2378-2388.	2.8	108
39	Heart failure specialization in Europe. European Journal of Heart Failure, 2016, 18, 347-349.	7.1	9
40	Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development. Cardiovascular Research, 2016, 111, 217-226.	3.8	24
41	CardioPulse Articles The Heart Failure Association of the European Society of Cardiology: Second decade of successGraduation of First Postgraduate Course in Heart FailureThe Postgraduate Course in Heart FailureThe second Postgraduate Course in Heart Failure: 2016â€“2017Leaders in cardiovascular medicine todayDr Marc Pfeffer PhD MDSettling scores with a failing heartPocket-sized ultrasound for nurses in heart failure?PARADIGM-HF trial most favoured atEuropean Society of CardiologyCongress London. European Heart Journal, 2016, 37, 425-436.	2.2	0
42	<scp>BNP</scp> in heart failure: even leucocytes cannot escape its influence. European Journal of Heart Failure, 2015, 17, 536-538.	7.1	2
43	Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the REâ€LY trial. Journal of Thrombosis and Haemostasis, 2015, 13, 699-707.	3.8	53
44	Mitochondrial Reprogramming Induced by CaMKIIÎ´ Mediates Hypertrophy Decompensation. Circulation Research, 2015, 116, e28-39.	4.5	47
45	Cardiac resynchronization therapy in mild heart failure should be reserved for true dyssynchronopathy. European Journal of Heart Failure, 2015, 17, 239-241.	7.1	0
46	Chagas, a cardiomyopathy emerging from obscurity. European Journal of Heart Failure, 2015, 17, 355-357.	7.1	5
47	Î²-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial. Cardiovascular Drugs and Therapy, 2015, 29, 277-285.	2.6	12
48	Loss of mitochondrial exo/endonuclease EXOG affects mitochondrial respiration and induces ROS-mediated cardiomyocyte hypertrophy. American Journal of Physiology - Cell Physiology, 2015, 308, C155-C163.	4.6	19
49	<scp>CaMKII</scp> confirms its promise in ischaemic heart disease. European Journal of Heart Failure, 2014, 16, 1268-1269.	7.1	3
50	Heart failure highlights in 2012â€“2013. European Journal of Heart Failure, 2014, 16, 122-132.	7.1	11
51	Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients. Clinical Research in Cardiology, 2014, 103, 467-476.	3.3	2
52	Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist. International Journal of Cardiology, 2013, 169, 385-393.	1.7	14
53	Suicidal erythrocyte death, eryptosis, as a novel mechanism in heart failure-associated anaemia. Cardiovascular Research, 2013, 98, 37-46.	3.8	26
54	AKIP1, a Cardiac Hypertrophy Induced Protein that Stimulates Cardiomyocyte Growth via the Akt Pathway. International Journal of Molecular Sciences, 2013, 14, 21378-21393.	4.1	17

#	Article	IF	Citations
55	Haemodilution is a mechanism of anaemia in patients with heart failure: reply. European Journal of Heart Failure, 2013, 15, 1074-1075.	7.1	0
56	The promise of CaMKII inhibition for heart disease: preventing heart failure and arrhythmias. Expert Opinion on Therapeutic Targets, 2013, 17, 889-903.	3.4	26
57	Erythropoietin and heart failure: the end of a promise?. European Journal of Heart Failure, 2013, 15, 479-481.	7.1	13
58	Imaging the cardiac diet. European Journal of Heart Failure, 2013, 15, 123-124.	7.1	3
59	AKIP1 Expression Modulates Mitochondrial Function in Rat Neonatal Cardiomyocytes. PLoS ONE, 2013, 8, e80815.	2.5	18
60	Heart failure highlights in 2011. European Journal of Heart Failure, 2012, 14, 1090-1096.	7.1	3
61	Sustained postoperative anaemia is associated with an impaired outcome after coronary artery bypass graft surgery: insights from the IMAGINE trial. Heart, 2011, 97, 1590-1596.	2.9	52
62	Apoptosis during CABG surgery with the use of cardiopulmonary bypass is prominent in ventricular but not in atrial myocardium. Netherlands Heart Journal, 2010, 18, 236-242.	0.8	9
63	Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart, 2010, 96, 1297-1302.	2.9	179
64	Bone marrow dysfunction in chronic heart failure patients. European Journal of Heart Failure, 2010, 12, 676-684.	7.1	86
65	Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovascular Research, 2010, 87, 30-39.	3.8	72
66	Anaemia is associated with shorter leucocyte telomere length in patients with chronic heart failure. European Journal of Heart Failure, 2010, 12, 348-353.	7.1	19
67	Differential associations between renal function and â€œmodifiableâ€•risk factors in patients with chronic heart failure. Clinical Research in Cardiology, 2009, 98, 121-129.	3.3	101
68	Erythropoietin levels in heart failure after an acute myocardial infarction: Determinants, prognostic value, and the effects of captopril versus losartan. American Heart Journal, 2009, 157, 91-96.	2.7	13
69	Erythropoietin Stimulates Normal Endothelial Progenitor Cell-Mediated Endothelial Turnover, but Attributes to Neovascularization Only in the Presence of Local Ischemia. Cardiovascular Drugs and Therapy, 2008, 22, 265-274.	2.6	51
70	Erythropoietin in cardiac disease: New features of an old drug. European Journal of Pharmacology, 2008, 585, 270-277.	3.5	18
71	Lowâ€dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. European Journal of Heart Failure, 2008, 10, 22-29.	7.1	72
72	Anemia in chronic heart failure: etiology and treatment options. Current Opinion in Cardiology, 2008, 23, 141-147.	1.8	25

#	Article	IF	Citations
73	Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. European Heart Journal, 2007, 28, 2018-2027.	2.2	210
74	Is Anemia in Chronic Heart Failure Caused by Iron Deficiency?. Journal of the American College of Cardiology, 2007, 49, 2301-2302.	2.8	17
75	Can Critically Short Telomeres Cause Functional Exhaustion of Progenitor Cells in Postinfarction Heart Failure?. Journal of the American College of Cardiology, 2007, 50, 1911-1912.	2.8	14
76	Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond. Current Heart Failure Reports, 2007, 4, 127-133.	3.3	9
77	A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study. Cardiovascular Drugs and Therapy, 2006, 20, 135-141.	2.6	176
78	Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. European Heart Journal, 2006, 28, 166-171.	2.2	134
79	Cytokine Responses to Stimulation of Whole Blood from Patients with Buruli Ulcer Disease in Ghana. Vaccine Journal, 2005, 12, 125-129.	3.1	47
80	Levels of Hematopoiesis Inhibitor N -Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure. Circulation, 2005, 112, 1743-1747.	1.6	120
81	Short-Chain Fatty Acids in the Metabolism of Heart Failure â€“ Rethinking the Fat Stigma. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	18